Vinod Ravi

机构：The University of Texas MD Anderson Cancer Center, Sarcoma Oncology Center · ORCID：0000-0001-6080-9336

发表论文 318 篇 · 总被引 6934 次 · h-index 44

代表论文

• SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (2025 · Nature · 被引 121)
• MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients (2024 · Future Oncology · 被引 19)
• Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial (2026 · The Lancet · 被引 10)
• Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience (2025 · Frontiers in Immunology · 被引 6)
• Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study. (2025 · Journal of Clinical Oncology · 被引 5)
• IoT and ML-driven framework for managing infectious disease risks in communal spaces: a post-COVID perspective (2025 · Frontiers in Public Health · 被引 4)